Accession Number: | 0001415889-22-003935 |
Date: | 2022-04-05 |
Issuer: | PTC THERAPEUTICS, INC. (PTCT) |
Original Submission Date: |
BOULDING MARK ELLIOTT
C/O PTC THERAPEUTICS, INC.
100 CORPORATE COURT
SOUTH PLAINFIELD, NJ 07080
Title of Security | Transaction Date | 2a. Deemed Execution Date | Transaction Code | Shares | Acquired or Disposed | Price per share | 5. Amount of Securities Beneficially Owned Following Reported Transaction | 6. Ownership Form Direct or Indirect | Nature of Indirect Ownership |
---|---|---|---|---|---|---|---|---|---|
COMMON STOCK | 2022-04-05 | M | 5 | a | $11.23 | 61,115 | direct | ||
COMMON STOCK | 2022-04-05 | S | 5 | d | $45.00 | 61,110 | direct |
Title of Derivative Security | Conversion or Exercise Price of Derivative Security | Transaction Date | Deemed Execution Date | Transaction Code | Number of Derivative Securities Acquired (A) or Disposed of (D) | Date Exercisable | Expiration Date | Title and Amount of Securities Underlying Derivative Security | Price of Derivative Security | Number of derivative Securities Beneficially Owned Following Reported Transaction(s) | Ownership Form: Direct (D) or Indirect (I) | Nature of Indirect Beneficial Ownership |
---|---|---|---|---|---|---|---|---|---|---|---|---|
STOCK OPTION (RIGHT TO BUY) | 11.23 | 2022-04-05 | deemed execution date | M | 5 (d) | 2027-01-02 | common stock 5 | $11.23 | 2,276 | direct | ||
STOCK OPTION (RIGHT TO BUY) | 51.0 | deemed execution date | 0 ( ) | 2025-01-01 | common stock 85,600 | $51.00 | 85,600 | direct | ||||
STOCK OPTION (RIGHT TO BUY) | 30.86 | deemed execution date | 0 ( ) | 2026-01-03 | common stock 70,000 | $30.86 | 70,000 | direct | ||||
STOCK OPTION (RIGHT TO BUY) | 33.02 | deemed execution date | 0 ( ) | 2029-01-21 | common stock 72,500 | $33.02 | 72,500 | direct | ||||
STOCK OPTION (RIGHT TO BUY) | 33.02 | deemed execution date | 0 ( ) | 2029-01-21 | common stock 17,500 | $33.02 | 17,500 | direct | ||||
STOCK OPTION (RIGHT TO BUY) | 51.16 | deemed execution date | 0 ( ) | 2030-01-28 | common stock 59,500 | $51.16 | 59,500 | direct | ||||
STOCK OPTION (RIGHT TO BUY) | 66.49 | deemed execution date | 0 ( ) | 2031-01-05 | common stock 59,500 | $66.49 | 59,500 | direct | ||||
STOCK OPTION (RIGHT TO BUY) | 38.1 | deemed execution date | 0 ( ) | 2032-01-06 | common stock 54,000 | $38.10 | 54,000 | direct |
ID | footnote |
---|---|
f1 | this transaction was effected pursuant to a written rule 10b5-1 plan adopted by the reporting person on december 2, 2021. |
f2 | currently exercisable. |
f3 | this option was granted on january 22, 2019 and vests over four years, with 25% of the shares underlying the option vesting on january 22, 2020, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning april 22, 2020. |
f4 | this option was granted on january 22, 2019 and vests over four years, with 50% of the shares underlying the option vesting on january 22, 2022, and the remaining 50% of the original number of shares underlying the option vesting on january 22, 2023. |
f5 | this option was granted on january 29, 2020, and vests over four years, with 25% of the shares underlying the option vesting on january 29, 2021, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on april 29, 2021. |
f6 | this option was granted on january 6, 2021, and vests over four years, with 25% of the shares underlying the option vesting on january 6, 2022, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on april 6, 2022. |
f7 | this option was granted on january 7, 2022, and vests over four years, with 25% of the shares underlying the option vesting on january 7, 2023, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on april 7, 2023. |